Rose Kushner Award Winners Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

BETHESDA, Md-The American Medical Writers Association (AMWA) has announced the winners of the 1995 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer, sponsored by the AMWA and Zeneca Pharmaceuticals.

BETHESDA, Md-The American Medical Writers Association (AMWA) hasannounced the winners of the 1995 Rose Kushner Awards for WritingAchievement in the Field of Breast Cancer, sponsored by the AMWAand Zeneca Pharmaceuticals.

  • Lay articles: Laurie Tarkan, How Daughters Face Their Mother'sBreast Cancer (McCall's), and Nicole Spelhaug, Breast Cancer:New Perspectives Can Replace Unrealistic Fears (supplement tothe Mayo Clinic Health Letter).
  • Scientific articles: Amy S. Langer and Karen Hassey Dow, TheBreast Cancer Advocacy Movement and Nursing (Oncology Nursing).
  • Scripts: Jane Glenn Haas, On-Line (The Orange Count News Channel).
  • Brochures and monographs: Aaron Rachel Rose, For Single WomenWith Breast Cancer (Y-ME National Breast Cancer Organization).

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content